CVN058, a 5-HT3 Receptor Antagonist, Shows Acute, Dose Dependent Improvement of Mismatch Negativity in a Double-Blind, Placebo-Controlled, Single Dose Cross-Over Study in Schizophrenia and Schizoaffective Disorder

Abstract

Serotonin receptor 3 (5-HT3R) antagonists have shown promise as a treatment for cognitive and early auditory processing deficits in schizophrenia. CVN058, a novel, brain-penetrant, highly potent and selective 5-HT3R antagonist, showed efficacy in rodent models of cognition and was safe and well-tolerated in Phase-1 studies.